Bristol-Myers Squibb Company
TRICYCLIC RHO KINASE INHIBITORS

Last updated:

Abstract:

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

29 Nov 2017

Issue date:

12 Sep 2019